文献速递头颈部肿瘤放疗姑息放疗与转移瘤

预防性NS-21维持皮肤湿度但不降低头颈癌放射性皮炎严重程度:随机对照试验

Prophylactic NS-21 maintains the skin moisture but does not reduce the severity of radiation dermatitis in patients with head and neck cancer: a randomized control trial.
PubMed 文献 · Radiat Oncol · 2019-05-30

本研究纳入30例接受放疗或同步放化疗的头颈癌患者,随机分配至NS-21乳膏组或对照组,每日照射皮肤涂抹三次。结果显示NS-21耐受良好且能维持皮肤湿度,但未显著降低急性放射性皮炎风险。

要点

  • NS-21组与对照组急性放射性皮炎发生率无显著差异(6.7% vs 26.7%,p=0.165)。
  • NS-21组最终治疗时中位皮肤湿度显著高于对照组(30.6 vs 27.3,p=0.013)。
  • 照射剂量47-70 Gy的皮肤发生3级放射性皮炎风险显著高于≤46 Gy(OR=31.06)。

核心结论

  • NS-21乳膏耐受良好且能有效维持皮肤湿度,但与对照组相比未显著降低头颈癌患者放疗或同步放化疗期间的急性放射性皮炎风险。

主要发现

  • 两组均未观察到严重不良事件;NS-21组1例患者在同步放化疗第3周右下肢颈部出现轻度瘙痒性皮炎。
  • 最终治疗时中位皮肤湿度NS-21组为30.6,对照组为27.3,差异显著(p=0.013)。
  • 皮肤湿度与急性放射性皮炎分级呈负相关(B=-0.04,p=0.005)。
  • 最终治疗时急性放射性皮炎发生率两组无显著差异(6.7% vs 26.7%,p=0.165)。
  • 照射剂量47-70 Gy的皮肤发生3级急性放射性皮炎风险高于≤46 Gy(OR=31.06,95%CI=5.95-162.21,p<0.001)。

关键数值与推荐

  • 急性放射性皮炎按CTCAE 4.0版每周记录。
  • NS-21或对照治疗每日三次,从放疗或同步放化疗开始至结束后2周或出现3级急性放射性皮炎。
  • 两组急性放射性皮炎风险无显著差异(OR=0.38,95%CI=0.08-1.74,p=0.212)。

临床怎么用

  • NS-21可用于维持头颈癌放疗患者照射皮肤湿度,但不应期望其显著降低急性放射性皮炎发生率。
  • 照射剂量47-70 Gy区域需重点关注3级急性放射性皮炎风险。

局限性

  • 样本量较小(30例),可能影响统计效能。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the practicality of NS-21 cream with regard to its skin-related toxicity in patients with head and neck cancer (HNC) who are undergoing concurrent chemoradiation therapy (CCRT) or radiotherapy (RT). METHODS: Between July 2015 and November 2017, 30 HNC patients who underwent RT or CCRT were randomly allocated to receive either NS-21 or control treatment on their irradiated skin three times per day, starting at the initiation of RT or CCRT and ending 2 weeks after the completion of RT or until the appearance of grade 3 acute radiation dermatitis (ARD). Dermatitis was recorded weekly according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Skin humidity was monitored by a digital moisture meter. The generalized estimating equation (GEE) and logit link function method were used for statistical analysis. RESULTS: No serious adverse events were observed in either group. Itching dermatitis occurred on the right lower neck in one patient of the NS-21 group during the 3rd week of CCRT, but the severity was mild. The median skin moisture value at the time of the final treatment was significantly different between the study and control groups (30.6 vs. 27.3, p = 0.013). Additionally, there was an inverse relationship between skin moisture and ARD grade (B = -0.04, p = 0.005). The incidence of ARD at the time of the last treatment was not significantly different between the study and control groups (6.7% vs 26.7%, p = 0.165). The risk of grade 3 ARD for skin that had received an irradiation dose of 47-70 Gy was higher than that of skin that had received an irradiation dose ≤46 Gy (OR = 31.06, 95% CI =5.95-162.21, p < 0.001). Nevertheless, the risk of ARD was not significantly different between the groups (OR = 0.38, 95% CI = 0.08-1.74, p = 0.212). CONCLUSIONS: NS-21 was well tolerated and effective for the maintenance of skin moisture; however, there was no statistically significant reduction in the risk of ARD in HNC patients undergoing RT or CCRT when compared with HNC patients in the control group. TRIAL REGISTRATION: The study was approved by the Institutional Review Board of Far Eastern Memorial Hospital ( FEMH-IRB , 104048-F), Registered 1st June 2015.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chou HL, Shueng PW, Liao LJ, et al. Prophylactic NS-21 maintains the skin moisture but does not reduce the severity of radiation dermatitis in patients with head and neck cancer: a randomized control trial. Radiat Oncol. 2019. PMID: 31146741. doi:10.1186/s13014-019-1302-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。